Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its proprietary recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

Poster Presentation

Titled: "Escherichia coli High Yield Recombinant Expression, Secretion and Amidation of the 39 Amino Acid GLP-1 Analog Peptide Exendin-4", and authored by Christopher P. Meenan, Frank V. Ritacco, Paul Van Duyne, Angelo P. Consalvo, Seth Pennington, Christina J. Sisk, Vicki L. Ray, and Nozer M. Mehta.

Oral Presentation

An oral presentation by Dr. Nozer Mehta, Unigene's Vice President Biological Research and Development, titled "Clinical Development Case Study: Optimizing a Solid Dosage Formulation for the Oral Delivery of Peptides" is scheduled to begin at 2:30 p.m. EDT on Wednesday, May 25, 2011.

Dr. Nozer Mehta, Vice President Biological Research and Development stated, "The TIDES Summit is considered one of the premier conferences focused on peptide based therapeutics. In the poster presentation, we are pleased to have the opportunity to showcase Unigene's high yield recombinant production technology as applied to Exendin-4, a currently marketed peptide. Our oral presentation highlights Unigene's tremendous progress in further optimizing our industry leading oral formulation by improving bioavailability, stability, and reducing variability. We will present data on the parameters of the optimization program that is the subject of a new patent application and the clinical use of the optimized tablets for the oral delivery of our PTH analog for the treatment of osteoporosis."